Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Ironwood Pharmaceuticals Inc (NASDAQ:IRWD)

15.72
Delayed Data
As of 4:00pm ET
 +0.51 / +3.35%
Today’s Change
13.43
Today|||52-Week Range
19.94
+2.81%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$2.3B

Company Description

Ironwood Pharmaceuticals, Inc. is a commercial biotechnology company, which discovers, develops and intends to commercialize differentiated medicines that improve patient's lives. Its products include linaclotide, a guanylate cyclase type-C agonist being developed for the treatment of patients with irritable bowel syndrome with constipation and chronic constipation; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook, Jr. and Gina Bornino Miller on January 5, 1998 and is headquartered in Cambridge, MA.

Contact Information

Ironwood Pharmaceuticals, Inc.
301 Binney Street
Cambridge Massachusetts 02142
P:(617) 621-7722
Investor Relations:
(617) 374-5082

Employees

Shareholders

Individual stakeholders8.42%
Mutual fund holders71.77%
Other institutional45.28%

Top Executives

Peter M. HechtChief Executive Officer & Director
William I. HuyettChief Operating Officer
Gina R. ConsylmanCFO, CAO, Controller & VP-Finance
Brian M. CaliSenior VP-Preclinical, Research & Development
Mark G. CurrieChief Scientific Officer & Senior Vice President